{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:26:43Z","timestamp":1792762003272,"version":"4.5.0"},"reference-count":98,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1001\/jamadermatol.2018.3447","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T13:00:54Z","timestamp":1542200454000},"page":"29","source":"Crossref","is-referenced-by-count":155,"title":["Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria"],"prefix":"10.1001","volume":"155","author":[{"given":"Michael D.","family":"Tharp","sequence":"first","affiliation":[{"name":"Department of Dermatology, Rush University Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Division of Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kavati","sequence":"additional","affiliation":[{"name":"US Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Respiratory Medical Unit, US Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Matrix45, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Denhaerynck","sequence":"additional","affiliation":[{"name":"Matrix45, Tucson, Arizona"},{"name":"Department of Public Health, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[{"name":"Matrix45, Tucson, Arizona"},{"name":"Associate Editor for Quantitative Methods, JAMA Dermatology"},{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona"},{"name":"Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Matrix45, Tucson, Arizona"},{"name":"Boston College Connell School of Nursing, Chestnut Hill, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"26","key":"doi180053r1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJM199506293322608","article-title":"Chronic urticaria.","volume":"332","author":"Greaves","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"doi180053r2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria.","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"issue":"3","key":"doi180053r3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5021\/ad.2009.21.3.226","article-title":"The impact of chronic idiopathic urticaria on quality of life in Korean patients.","volume":"21","author":"Kang","year":"2009","journal-title":"Ann Dermatol"},{"issue":"3","key":"doi180053r4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/all.2011.66.issue-3","article-title":"Unmet clinical needs in chronic spontaneous urticaria: a GA2LEN task force report.","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"issue":"3","key":"doi180053r5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi180053r6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"doi180053r7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"doi180053r8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jval.2015.09.2938","article-title":"The \u201cefficacy-effectiveness gap\u201d: historical background and current conceptualization.","volume":"19","author":"Nordon","year":"2016","journal-title":"Value Health"},{"issue":"7","key":"doi180053r9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrd3501","article-title":"Bridging the efficacy-effectiveness gap: a regulator\u2019s perspective on addressing variability of drug response.","volume":"10","author":"Eichler","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"doi180053r10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/all.12815","article-title":"\u2018Real-life\u2019 effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.","volume":"71","author":"Abraham","year":"2016","journal-title":"Allergy"},{"issue":"5","key":"doi180053r11","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\u201cReal-life\u201d effectiveness studies of omalizumab in patients with severe allergic asthma: meta-analysis.","volume":"5","author":"Alhossan","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"doi180053r12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","article-title":"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of \u2018real-world\u2019 evidence.","volume":"18","author":"Bernstein","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"doi180053r13","doi-asserted-by":"publisher","first-page":"W65-94","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"issue":"15","key":"doi180053r14","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"6","key":"doi180053r15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/0256-4947.70567","article-title":"Omalizumab therapy in three patients with chronic autoimmune urticaria.","volume":"30","author":"Al-Ahmad","year":"2010","journal-title":"Ann Saudi Med"},{"issue":"3","key":"doi180053r16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/dth.2013.26.issue-3","article-title":"Omalizumab in chronic urticaria: a retrospective series of 15 cases.","volume":"26","author":"Armengot-Carbo","year":"2013","journal-title":"Dermatol Ther"},{"issue":"1","key":"doi180053r17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000453453","article-title":"D-dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria.","volume":"172","author":"Asero","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"doi180053r18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.anai.2016.08.006","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.","volume":"117","author":"Bongiorno","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"doi180053r19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/jde.2012.39.issue-5","article-title":"Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey.","volume":"39","author":"B\u00fcy\u00fck\u00f6zt\u00fcrk","year":"2012","journal-title":"J Dermatol"},{"issue":"4","key":"doi180053r20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ad.2016.10.005","article-title":"Eficacia y seguridad de omalizumab en un paciente con urticaria cr\u00f3nica espont\u00e1nea e infecci\u00f3n activa por el virus de la hepatitis B.","volume":"108","author":"Chicharro","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"doi180053r21","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaad.2015.12.052","article-title":"The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: retrospective chart review.","volume":"74","author":"Clark","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi180053r22","first-page":"242","article-title":"Use of omalizumab in the treatment of chronic urticaria.","volume":"48","author":"Cordeiro Moreira","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"4","key":"doi180053r23","first-page":"145","article-title":"Omalizumab use during pregnancy for CIU: a tertiary care experience.","volume":"48","author":"Cuervo-Pardo","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"doi180053r24","first-page":"64","article-title":"Omalizumab in the treatment of chronic spontaneous urticaria\u2014literature review and own experience.","volume":"103","author":"Dawicka","year":"2016","journal-title":"Przegl Dermatol"},{"issue":"6","key":"doi180053r25","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/bjd.15074","article-title":"Home self-administration of omalizumab for chronic spontaneous urticaria.","volume":"175","author":"Denman","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi180053r26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2340\/00015555-2654","article-title":"Basophil FceRI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy.","volume":"97","author":"Deza","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"doi180053r27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.7705\/biomedica.v33i4.782","article-title":"Omalizumab: opci\u00f3n terap\u00e9utica para la urticaria cr\u00f3nica espont\u00e1nea de dif\u00edcil control con vasculitis asociada, reporte de tres casos.","volume":"33","author":"D\u00edez","year":"2013","journal-title":"Biomedica"},{"issue":"2","key":"doi180053r28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000444985","article-title":"Omalizumab in chronic spontaneous urticaria: A Brazilian real-life experience.","volume":"169","author":"Ensina","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"doi180053r29","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jaci.2017.08.007","article-title":"Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.","volume":"140","author":"Ertas","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi180053r30","first-page":"82","article-title":"Adverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness?","volume":"15","author":"Ertas","year":"2016","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"5","key":"doi180053r31","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jaci.2010.12.1085","article-title":"Omalizumab is effective in nonautoimmune urticaria.","volume":"127","author":"Ferrer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi180053r32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5114\/pdia.2014.44023","article-title":"Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases.","volume":"31","author":"Fiorino","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"issue":"3","key":"doi180053r33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"doi180053r34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjd.14540","article-title":"Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients.","volume":"175","author":"Ghazanfar","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi180053r35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1684\/ejd.2016.2809","article-title":"Omalizumab: what benefits should we expect?","volume":"26","author":"Gim\u00e9nez-Arnau","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"4","key":"doi180053r36","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4103\/0019-5154.84737","article-title":"Omalizumab in treatment-resistant chronic spontaneous urticaria.","volume":"56","author":"Godse","year":"2011","journal-title":"Indian J Dermatol"},{"issue":"2","key":"doi180053r37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.anai.2016.06.010","article-title":"Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.","volume":"117","author":"G\u00f3mez-Vera","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"doi180053r38","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/jdv.14034","article-title":"Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases.","volume":"31","author":"Gonz\u00e1lez-Medina","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi180053r39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/all.2010.66.issue-2","article-title":"Omalizumab\u2014an effective and safe treatment of therapy-resistant chronic spontaneous urticaria.","volume":"66","author":"Groffik","year":"2011","journal-title":"Allergy"},{"issue":"2","key":"doi180053r40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.anai.2015.05.010","article-title":"Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.","volume":"115","author":"Har","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"doi180053r41","first-page":"88","article-title":"Successful omalizumab treatment in HIV positive patient with chronic spontaneous urticaria: a case report.","volume":"49","author":"Iemoli","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"5","key":"doi180053r43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/ced.12320","article-title":"Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.","volume":"39","author":"Kai","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"doi180053r44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab.","volume":"122","author":"Kaplan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"doi180053r45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/0394632015623795","article-title":"Effective treatment of different phenotypes of chronic urticaria with omalizumab: case reports and review of literature.","volume":"29","author":"Kasperska-Zajac","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"doi180053r46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.02.283","article-title":"Management of chronic inducible urticaria according to the guidelines: a prospective controlled study.","volume":"87","author":"Kocat\u00fcrk","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"5","key":"doi180053r47","first-page":"205","article-title":"Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?","volume":"48","author":"Konstantinou","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"3","key":"doi180053r48","first-page":"57","article-title":"Omalizumab in chronic urticaria: our experience and literature review.","volume":"23","author":"Ko\u0161nik","year":"2014","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"2","key":"doi180053r49","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/09546634.2016.1200710","article-title":"Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.","volume":"28","author":"Kulthanan","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"doi180053r50","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1517\/14712598.2013.822484","article-title":"Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice.","volume":"13","author":"Labrador-Horrillo","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"doi180053r51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.enfcli.2017.03.010","article-title":"Mejora de la calidad de vida de los pacientes con urticaria cr\u00f3nica espont\u00e1nea tratados con omalizumab en vida real.","volume":"27","author":"Larrea-Baca","year":"2017","journal-title":"Enferm Clin"},{"issue":"2","key":"doi180053r52","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5021\/ad.2013.25.2.242","article-title":"A long-term case series study of the effect of omalizumab on chronic spontaneous urticaria.","volume":"25","author":"Lef\u00e9vre","year":"2013","journal-title":"Ann Dermatol"},{"issue":"4","key":"doi180053r53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.anai.2015.01.014","article-title":"Expanding the spectrum: chronic urticaria and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.","volume":"114","author":"Lundberg","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"doi180053r54","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jaci.2010.05.047","article-title":"Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab.","volume":"126","author":"Magerl","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"doi180053r55","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ad.2016.12.012","article-title":"Manejo de la urticaria cr\u00f3nica espont\u00e1nea en la pr\u00e1ctica cl\u00ednica diaria siguiendo las indicaciones de la gu\u00eda EAACI\/GA(2)LEN\/EDF\/WAO.","volume":"108","author":"Mar\u00edn-Caba\u00f1as","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"doi180053r56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.","volume":"73","author":"Metz","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"3","key":"doi180053r57","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamadermatol.2013.8705","article-title":"Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.","volume":"150","author":"Metz","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"6","key":"doi180053r58","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4168\/aair.2012.4.6.357","article-title":"Effects of omalizumab treatment in patients with refractory chronic urticaria.","volume":"4","author":"Nam","year":"2012","journal-title":"Allergy Asthma Immunol Res"},{"issue":"6","key":"doi180053r59","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/pai.2015.26.issue-6","article-title":"Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series.","volume":"26","author":"Netchiporouk","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"doi180053r60","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jaip.2015.11.025","article-title":"Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.","volume":"4","author":"Palacios","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"doi180053r61","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/ced.2017.42.issue-7","article-title":"Long-term management of chronic spontaneous urticaria with omalizumab.","volume":"42","author":"Pinto Gouveia","year":"2017","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"doi180053r62","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/ppul.v52.5","article-title":"Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria.","volume":"52","author":"Porcaro","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"doi180053r63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40261-015-0267-9","article-title":"Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.","volume":"35","author":"Romano","year":"2015","journal-title":"Clin Drug Investig"},{"issue":"8","key":"doi180053r64","first-page":"487","article-title":"Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.","volume":"16","author":"Rottem","year":"2014","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"doi180053r65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13223-015-0088-7","article-title":"Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care.","volume":"11","author":"Savic","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"doi180053r66","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jaip.2016.08.010","article-title":"The comparative safety of multiple alternative agents in refractory chronic urticaria patients.","volume":"5","author":"Seth","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"doi180053r67","first-page":"267","article-title":"A case of refractory chronic spontaneous urticaria treated with omalizumab.","volume":"26","author":"Shahzad","year":"2016","journal-title":"J Pak Assoc Dermatol"},{"issue":"2","key":"doi180053r68","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.aller.2013.11.007","article-title":"Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria.","volume":"43","author":"Silva","year":"2015","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"2","key":"doi180053r69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.anai.2012.11.022","article-title":"Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.","volume":"110","author":"Song","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"doi180053r70","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1081-1206(10)60644-8","article-title":"Effect of omalizumab on patients with chronic urticaria.","volume":"99","author":"Spector","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"doi180053r71","doi-asserted-by":"publisher","first-page":"467","DOI":"10.4103\/0019-5154.185745","article-title":"Treatment of chronic spontaneous urticaria with a single dose of omalizumab: a study of four cases.","volume":"61","author":"Subramaniyan","year":"2016","journal-title":"Indian J Dermatol"},{"key":"doi180053r72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/jdv.2015.29.issue-S3","article-title":"Treatment dilemmas in chronic urticaria.","volume":"29","author":"Sussman","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi180053r73","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.anai.2013.12.005","article-title":"Real-life experiences with omalizumab for the treatment of chronic urticaria.","volume":"112","author":"Sussman","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"doi180053r74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.anai.2015.05.005","article-title":"Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?","volume":"115","author":"Tontini","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"doi180053r75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.alit.2017.05.003","article-title":"Treatment and retreatment with omalizumab in chronic spontaneous urticaria: real life experience with twenty-five patients.","volume":"67","author":"T\u00fcrk","year":"2018","journal-title":"Allergol Int"},{"issue":"3","key":"doi180053r76","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jaci.2013.10.015","article-title":"An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.","volume":"133","author":"Uysal","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi180053r77","first-page":"253","article-title":"Treatment of chronic urticaria with omalizumab.","volume":"24","author":"Van Den Elzen","year":"2014","journal-title":"Ned Tijdschr Dermatol Venereol"},{"issue":"4","key":"doi180053r78","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2340\/00015555-0884","article-title":"Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab.","volume":"90","author":"Vestergaard","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi180053r79","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2500\/aap.2013.34.3694","article-title":"Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria.","volume":"34","author":"Viswanathan","year":"2013","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"doi180053r80","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/BF03362514","article-title":"Omalizumab treatment of different urticaria subtypes.","volume":"20","author":"Wieczorek","year":"2011","journal-title":"Allergo J"},{"issue":"1","key":"doi180053r81","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40413-016-0127-y","article-title":"Omalizumab for chronic urticaria in Latin America.","volume":"9","author":"Wilches","year":"2016","journal-title":"World Allergy Organ J"},{"issue":"6","key":"doi180053r82","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1398-9995.2008.01726.x","article-title":"How to assess disease activity in patients with chronic urticaria?","volume":"63","author":"Mlynek","year":"2008","journal-title":"Allergy"},{"issue":"1","key":"doi180053r83","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.anai.2011.09.008","article-title":"Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.","volume":"108","author":"Mathias","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"doi180053r84","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"doi180053r85","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-3-36","article-title":"Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria.","volume":"3","author":"Shikiar","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"doi180053r86","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/all.2005.60.issue-8","article-title":"A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL).","volume":"60","author":"Baiardini","year":"2005","journal-title":"Allergy"},{"issue":"3","key":"doi180053r88","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7","key":"doi180053r89","doi-asserted-by":"publisher","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis.","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"doi180053r90","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data.","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"issue":"20","key":"doi180053r91","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/sim.4247","article-title":"Multivariate meta-analysis: potential and promise.","volume":"30","author":"Jackson","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"doi180053r93","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi180053r94","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaip.2017.10.001","article-title":"The urticaria activity score\u2014validity, reliability, and responsiveness.","volume":"6","author":"Hawro","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"doi180053r95","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/all.2018.73.issue-1","article-title":"Comparison and interpretability of the available urticaria activity scores.","volume":"73","author":"Hawro","year":"2018","journal-title":"Allergy"},{"key":"doi180053r96","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2288-12-111","article-title":"Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature.","volume":"12","author":"Gagnier","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"449","key":"doi180053r97","first-page":"89","article-title":"A nonparametric \u201ctrim and fill\u201d method of accounting for publication bias in meta-analysis.","volume":"95","author":"Duval","year":"2000","journal-title":"J Am Stat Assoc"},{"issue":"7109","key":"doi180053r98","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"doi180053r87","first-page":"567","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"doi180053r42","unstructured":"IraniC, NahasO. Real-life experience of clinical efficacy of omalizumab use in the Middle East: Should we also be concerned about parasites? Clinical Anti-Inflammatory & Anti-Allergy Drugs [discontinued]. 2015;2(1):43-46. http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=2212-7038&volume=2&issue=1&spage=43. Accessed September 4, 2018."},{"key":"doi180053r92","doi-asserted-by":"crossref","unstructured":"WhiteIR. Multivariate random-effects meta-regression: updates to mvmeta.Stata J. 2011;11(2):255-270. https:\/\/econpapers.repec.org\/article\/tsjstataj\/v_3a11_3ay_3a2011_3ai_3a2_3ap_3a255-270.htm. Accessed August 23, 2018.","DOI":"10.1177\/1536867X1101100206"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2713952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T02:19:10Z","timestamp":1605406750000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.3447"}},"subtitle":["A Meta-analysis of \u201cReal-world\u201d Evidence"],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.3447","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}